| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive Chairman | Chief Executive Officer
2 companies
Philip Astley-Sparke is Director at REPL, with reported holdings spanning 2 companies. Philip Astley-Sparke's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $28.4M at current prices.
Our model assigns Philip Astley-Sparke a below-average insider score of 47/100, based on 5 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +15.7%.
Philip Astley-Sparke's largest disclosed position is in REPL as Director, worth about $28.1M. The REPL filings lean toward selling, a net 302,398 shares.
Philip Astley-Sparke has 36 Form 4 filings on record from January 2017 to August 2026, across 3 companies: Director at Replimune Group (REPL), 2018–2026; Director at enGene Therapeutics (ENGN), 2025–2026; Director at uniQure (QURE), 2017–2021.
The 67 reported transactions were 41 open-market sales, 15 option or other derivative awards, 8 stock awards and 3 gifts.
Counted by filing, the open-market trades come to no purchases and 19 sales worth about $8.4M.
The largest open-market sale was 50,000 shares of REPL at an average $43.76 on January 19, 2021, about $2.2M.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | REPL Replimune Group, Inc. | Director | Sell | 17,657 | $5.08 | $89,697.56 | -1.2% | +192.0% | - | |
| May 20, 2025 | REPL Replimune Group, Inc. | Director | Sell | 32,279 | $8.06 | $260,168.74 | -2.2% | -42.0% | -43.9% | |
| May 16, 2024 | REPL Replimune Group, Inc. | Executive Chairman | Sell | 37,928 | $6.47 | $245,394.16 | -2.5% | +46.7% | +16.8% | |
| May 16, 2023 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 17,902 | $18.05 | $323,131.10 | -1.2% | +6.5% | -63.2% | |
| May 16, 2022 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 9,632 | $14.59 | $140,530.88 | -0.7% | +42.1% | +27.3% | |
| Mar 2, 2021 | QURE Uniqure N.V. | Director | Sell | 504 | $37.60 | $18,950.40 | -4.8% | - | - | |
| Jan 19, 2021 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 50,000 | $43.76 | $2,187,789.71 | -3.8% | - | - | |
| Dec 10, 2020 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 50,000 | $43.40 | $2,169,873.59 | -3.7% | - | - | |
| Jan 30, 2020 | QURE Uniqure N.V. | Director | Sell | 807 | $59.23 | $47,798.61 | -11.8% | - | - | |
| Nov 6, 2019 | REPL Replimune Group, Inc. | Executive Chairman | Sell | 29,000 | $17.01 | $493,290.00 | -2.1% | - | - |